Patient-reported event	Baseline (N=20)	3 months (N=20)	6 months (N=20)	12 months (N=10)	p
FREQUENCY					
Abdominal pain	20%	60%	50%	50%	0.06
Alopecia	15%	35%	45%	30%	0.23
Arthralgia	50%	80%	75%	60%	0.18
Constipation	50%	70%	55%	60%	0.63
Diarrhoea	25%	40%	45%	70%	0.14
Headache	50%	35%	55%	60%	0.54
Myalgia	60%	90%	85%	90%	0.10
Nausea	25%	50%	30%	30%	0.44
Peripheral edema	20%	10%	30%	20%	0.48
Vomiting	5%	25%	20%	10%	0.35
SEVERITY					
Abdominal pain	10%	55%	40%	40%	0.02
Arthralgia	45%	80%	75%	60%	0.10
Asthenia/Fatigue	60%	90%	90%	80%	0.06
Constipation	50%	65%	50%	40%	0.57
Decreased appetite	35%	65%	75%	40%	0.04
Dysgeusia	10%	35%	45%	30%	0.09
Hand-foot syndrome	20%	40%	55%	40%	0.16
Headache	50%	60%	45%	20%	0.23
Myalgia	55%	85%	80%	60%	0.15
Nausea	20%	45%	30%	20%	0.33
Peripheral edema	15%	10%	10%	20%	0.89
Stomatitis	10%	35%	40%	40%	0.12
Xerostomia	25%	70%	60%	70%	0.02
Vomiting	5%	25%	15%	10%	0.39
INTERFERENCE ON DAILY ACTIVITIES					
Abdominal pain	5%	55%	40%	40%	<0.01
Arthralgia	45%	75%	75%	70%	0.13
Asthenia/Fatigue	45%	95%	90%	80%	<0.01
Constipation	25%	55%	45%	40%	0.29
Decreased appetite	30%	60%	70%	40%	0.06
Headache	45%	60%	40%	10%	0.07
Myalgia	55%	85%	70%	60%	0.19
Peripheral edema	15%	10%	10%	20%	0.89
Stomatitis	10%	30%	25%	30%	0.43
PRESENCE					
Dysphonia	65%	85%	70%	70%	0.53
Rash	10%	25%	35%	40%	0.20

Supplementary Table 2. Percentage of patients perceiving the presence and/or any degree of frequency, severity, interference on daily activities of symptomatic AEs at baseline and during treatment with LEN (according to PRO-CTCAE questionnaires).

Abbreviations: AEs, adverse events; PRO-CTCAE, Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events; LEN, lenvatinib.